Episode 096: Treatment of CLL

Chronic Lymphocytic Leukemia (CLL) management prioritizes a watch-and-wait approach for asymptomatic patients, as early intervention with agents like ibrutinib fails to improve overall survival despite delaying disease progression. Treatment initiation is reserved for symptomatic patients, those with progressive cytopenias, or individuals experiencing recurrent autoimmune complications like warm autoimmune hemolytic anemia. Current therapeutic strategies center on choosing between fixed-duration regimens, such as venetoclax combined with obinutuzumab, and continuous therapy using BTK inhibitors. Newer-generation BTK inhibitors like acalabrutinib and zanabrutinib offer superior toxicity profiles compared to earlier agents, specifically reducing risks of atrial fibrillation and hypertension. Clinical selection depends on balancing these side-effect profiles, the logistical burden of frequent laboratory monitoring for tumor lysis syndrome in fixed-duration protocols, and individual patient comorbidities, ultimately aiming to optimize long-term outcomes while maintaining quality of life.